Battered XenoPort Holds On For April PDUFA Date For Horizant

XenoPort Inc. is even more focused on the April 6 review deadline for its lead candidate, Horizant, for restless leg syndrome, after its second-string compound came up short in a Phase IIb trial in gastroesophageal reflux disease.